ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Protocol ID
PEPN2121
Disease (Sub Disease)
Multiple tumour types
Diagnosis Stage
Newly diagnosed
Relapsed/Refractory
Sponsor
National Cancer Institute (NCI)
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Months and older  
International registry ID's
NCT05286801
Back to Registry
Study Title A Phase 1/2 Study of Tiragolumab and Atezolizumab in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Protocol ID PEPN2121
Disease (Sub Disease) Multiple tumour types
Diagnosis Stage Newly diagnosed
Relapsed/Refractory
Sponsor National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT05286801
Trial Status Preparing to Open
Study Type Treatment
Phase Phase 1/2
Age Eligibility 12 Months and older  
International registry ID's NCT05286801

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168